Drug Profile
SIG 1451
Alternative Names: SIG1451Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Signum Biosciences
- Class Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action G protein-coupled receptor modulators; Signal transduction pathway inhibitors; Toll-like receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atopic dermatitis
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Atopic-dermatitis in USA (Topical)
- 15 Feb 2017 Preclinical trials in Atopic dermatitis in USA (Topical) (Signum Biosciences pipeline, February 2016)
- 15 Feb 2017 Signum Biosciences receives SBIR phase IIB grant from NIAID for SIG 1451 development in Atopic dermatitis